Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 464

Sort by

Sort Order Select

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy of Luspatercept on Transfusion Burden and Cytopenias in Intermediate, High, and Very High Risk Myelodysplastic Syndromes

Daniel Leonard, David Sallman, Kelly Pugh, Christopher S. Bell, Najla H. Al Ali, Uma Borate, Rami S. Komrokji, Andrew M. Brunner

Blood (2024) 144 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2024-207880

Published: 2024

Journal Articles

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

John O. Mascarenhas, Claire Harrison, Prithviraj Bose, Jean-Jacques Kiladjian, Alessandro Lucchesi, Alessandro Maria Vannucchi, Tymara Berry, Jennifer Riggs, Lixian Peng, Fei Huang, Ying Wan, Vivian Rodolf, Judy Ho, Shyamala Navada, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 1808.1.

https://doi.org/10.1182/blood-2024-199235

Published: 2024

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Blood (2024) 144 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2024-201613

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit Rampal, Daniel J DeAngelo, Virginia O. Volpe, Kristen M. Pettit, Gerard Hoehn, Sasa Dimitrijevic, Rami S. Komrokji, Eric Padron

Blood (2024) 144 (Supplement 1): 4569.2.

https://doi.org/10.1182/blood-2024-211148

Published: 2024

Journal Articles

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Mikkael A. Sekeres, Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Maria Diez-Campelo, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcarcel, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Esther Natalie Oliva

Blood (2024) 144 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2024-199636

Published: 2024

Journal Articles

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Mikkael A. Sekeres, Sangeetha Venugopal, Namrata S. Chandhok, Justin M. Watts, Terrence Bradley, Justin Taylor, David Sallman, Zhuoer Xie, Eric Padron, Shelby Sullivan, Emily Zyborowicz, Jeffrey Carter, Cherilyn Heggen, Lindsay Gurska, Rami S. Komrokji

Blood (2024) 144 (Supplement 1): 3679.

https://doi.org/10.1182/blood-2024-203444

Published: 2024

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Jeremy V. DiGennaro, George Concepcion, Najla H. Al Ali, Onyee Chan, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, David Sallman, Ashwin Kishtagari, Pankit Vachhani, John O. Mascarenhas, Rami S. Komrokji, Andrew T. Kuykendall

Blood (2024) 144 (Supplement 1): 4561.

https://doi.org/10.1182/blood-2024-202579

Published: 2024

Journal Articles

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

Katherine Tobon, Kylie Consalvo, Syeda Saba Kareem, Jeffrey E Lancet, Rami S. Komrokji, Javier Pinilla-Ibarz, David Sallman, Jennifer Eatrides, Alison R. Walker, Julio C. Chavez, Leidy Lismeris Isenalumhe, Bijal D Shah

Blood (2024) 144 (Supplement 1): 2820.

https://doi.org/10.1182/blood-2024-201486

Published: 2024

Journal Articles

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

Onyee Chan, Kendra L. Sweet, Chetasi Talati, Fatima Tuz Zahra, Lisa Ann Nardelli, Jatinder K. Lamba, Jongphil Kim, Jinming Song, Zhuoer Xie, Seongseok Yun, Andrew T. Kuykendall, Eric Padron, Alison R. Walker, Rami S. Komrokji, Jeffrey E Lancet, David Sallman

Blood (2024) 144 (Supplement 1): 4270.

https://doi.org/10.1182/blood-2024-206161

Published: 2024

Journal Articles

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Jeremy V. DiGennaro, Dimitrios Drekolias, Najla H. Al Ali, Onyee Chan, Seongseok Yun, Alison R. Walker, Zhuoer Xie, Eric Padron, Jeffrey E Lancet, Rami S. Komrokji, David Sallman

Blood (2024) 144 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2024-208927

Published: 2024

Journal Articles

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Blood (2024) 144 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2024-209541

Published: 2024

Journal Articles

Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2024-206248

Published: 2024

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Blood (2024) 144 (Supplement 1): 666.

https://doi.org/10.1182/blood-2024-194405

Published: 2024

Journal Articles

Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium

Blood (2024) 144 (Supplement 1): 665.

https://doi.org/10.1182/blood-2024-200184

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Efficacy of Luspatercept on Transfusion Burden and Cytopenias in Intermediate, High, and Very High Risk Myelodysplastic Syndromes

Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1 del5q): Outcomes and Response to Treatment

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Post-Approval Utilization of Pacritinib and Momelotinib in Patients with Myelofibrosis and Analysis of Early Treatment Outcomes

Efficacy of Combination Blinatumomab and Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CMLBP) in a Real World Setting

Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with a Hypomethylating Agent (HMA) and Venetoclax - Focus on Antifungal (AF) Prophylaxis and Molecular Subset Outcomes

Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology

Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))

Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only